openPR Logo
Press release

Better management of insulin resistance needed for UAE women with Polycystic Ovarian Syndrome

10-01-2013 05:08 PM CET | Health & Medicine

Press release from: Informa Life Sciences Exhibitions

Better management of insulin resistance needed for UAE women

Polycystic Ovary Syndrome (PCOS) is one of the most common female hormonal disturbances in the Middle East. The relationship between PCOS and insulin resistance is particularly important here in the UAE where 1 in 5 of the female population suffer from type 2 diabetes and other metabolic syndromes.

Professor Samia Farghaly, Head of Academic Department, Primary Healthcare, Dubai Health Authority, Dubai, UAE, will be addressing the issue of ‘Investigation and Management of Polycystic Ovary Syndrome’ at the Family Medicine Conference held at the Abu Dhabi Medical Congress & Exhibition from 27-29 October 2013 at the Abu Dhabi National Exhibition Centre.

According to Professor Farghaly, “The incidence of polycystic ovarian syndrome in a multitude of studies has ranged from as low as 10% to as high as 21% of the fertile female population. Having this condition could lead to a number of physiological, physical and psychological changes. Particularly, the prevalence of type 2 diabetes and other metabolic syndromes of the female population of the UAE and its relation to PCOS is well known.”

Women who suffer from PCOS show a variety of symptoms. According to the most widely used diagnostic criteria (Rotterdam Criteria for Diagnosis of PCOS), at least two of the following need to be present to confirm a diagnosis (after excluding other causes): oligoovulation and/or anovulation (associated with irregular (or cessation of) menstruation), hyperandrogenism (demonstrated clinically by increased body hair, and in more severe cases, hair loss), and polycystic ovaries, with the exclusion of other aetiologies.

“For many of the patients that visit my practice here in Dubai, PCOS is a common issue. We have cases coming in ranging from adolescents suffering from irregular periods, to married women suffering from infertility. Also, genetically, there is an association between the syndrome and insulin resistance which can even be evident in females who, at times, have lean bodies,” says Dr Farghaly.

There are other symptoms that women may experience related to PCOS which are metabolic and psychological. Weight gain and obesity are also common, along with a disturbance in the lipid profile of women with PCOS, typically demonstrated with blood tests. Psychological symptoms of PCOS include several conditions such as anxiety, depression, eating disorders, and psychosexual dysfunctions. Mood swings, accompanied with sleep irregularities and an abnormality of social interaction and personal motivation are also common for this condition.

According to Dr Farghaly, the best first-line treatment for PCOS is a lifestyle modification that involves exercise and a balanced diet. Managing the patient’s BMI (body mass index) is key to resolving PCOS, and reducing the BMI to

The Life Sciences Division comprises of 21 exhibitions covering the Middle Eastern, African, Asian, US and European markets. Across the year, our events attract over 5,000 exhibitors, 100,000 visitors and 13,000 delegates.

Dubai, United Arab Emirates

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Better management of insulin resistance needed for UAE women with Polycystic Ovarian Syndrome here

News-ID: 271820 • Views:

More Releases from Informa Life Sciences Exhibitions

3rd edition of MEDLAB Asia Pacific unveils state of the art laboratory innovations
3rd edition of MEDLAB Asia Pacific unveils state of the art laboratory innovatio …
Singapore, Singapore: The 3rd MEDLAB Asia Pacific Exhibition and Conference, organised by Informa Life Sciences Exhibitions commenced today and will continue until March 24 2016. It is held at the Sands Expo and Convention Centre, Singapore. The conference programme will featured in total nine CME-accredited conference tracks, accredited by the Singapore Medical Council. The exhibition will feature some of the key industry leaders such as, BioMerieux, Bio-Rad, EUROIMMUN, Siemens, Abbott,
Building Healthcare Exhibition delivers vital platform for decision makers in the Middle East industry
Building Healthcare Exhibition delivers vital platform for decision makers in th …
Dubai, UAE: Building Healthcare Exhibition & Conferences, organised by Informa Life Sciences Exhibitions, will take place 30 May - June 1 2016, at the Dubai International Convention and Exhibition Centre. The exhibition will bring together more than 6,000 leading investors, healthcare CEOs, government representatives, IT decision makers, architects, and more, to discuss the future of healthcare and source the most cutting-edge technologies, products and services available to ensure the
Total Laboratory Automation Key Topic at MEDLAB Asia Pacific 2016
Total Laboratory Automation Key Topic at MEDLAB Asia Pacific 2016
Singapore: Laboratories are under immense pressure to improve turnaround times, reduce human error rates, and improve efficiency while reducing costs. Those are the drivers for today’s automation of most of the clinical laboratories. Laboratory automation stands for the use of technology to minimalize or even eliminate manual handling of equipment and processes. In today’s fast moving healthcare industry, automation becomes crucial in laboratories for handling high volumes of samples at
Up to 30% of women in the GCC and South Asia suffer from infertility resulting from PCOS
Up to 30% of women in the GCC and South Asia suffer from infertility resulting f …
Dubai, UAE: There is a high incidence of polycystic ovarian syndrome (PCOS) in the Middle East/GCC region mainly due to hereditary and ethnic influences. Approximately up to 20-25% of women in the GCC of Middle Eastern and South Asian ethnicity suffer from PCOS. Experts believe that cases can reach 30% or even higher in the subfertility population in the region. The Obs Gyne Conference aims to tackle the different challenges,

All 4 Releases


More Releases for PCOS

Global Polycystic Ovary Syndrome (PCOS) Market Research and Forecast 2018-2023
Global polycystic ovary syndrome market size, share, market trends, research and analysis report by diagnosis (ultrasound, pelvic exam, blood test) by treatment (ovarian wedge resection, laparoscopic ovarian drilling, acupuncture) forecast 2018-2023 According to the OMR analysis, the global polycystic ovarian syndrome is growing at a significant rate during 2018-2023. The global polycystic ovarian syndrome has been growing significantly due to initiatives taken by the government authorities regarding early diagnosis of the
Polycystic Ovary Syndrome (PCOS) Drugs Market 2018: BIOCAD, Merck KGaA, AstraZen …
Qyresearchreports include new market research report “2018-2025 Polycystic Ovary Syndrome (PCOS) Drugs Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” to its huge collection of research reports. The global Polycystic Ovary Syndrome (PCOS) Drugs market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017
Polycystic Ovary Syndrome (PCOS) Drugs Market 2018: BIOCAD, Merck KGaA, AstraZen …
Qyresearchreports include new market research report “2018-2025 Polycystic Ovary Syndrome (PCOS) Drugs Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” to its huge collection of research reports. The global Polycystic Ovary Syndrome (PCOS) Drugs market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017
Polycystic Ovarian Syndrome (PCOS) Treatment Market Healthcare, Clinical Reviews …
Qyresearchreports include new market research report Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Size, Status and Forecast 2022 to its huge collection of research reports. The growth trajectory of the global Polycystic Ovarian Syndrome (PCOS) Treatment market is shaped by a wide range of strategic factors and demand dynamics, a critical assessment of which is given in this report. The market is also influenced by changes in governmental regulations in key
Discover the Growth of the Polycystic Ovarian Syndrome (PCOS) Therapeutics Marke …
Polycystic ovarian syndrome (PCOS) is an endocrine disorder observed in females during their reproductive age, due to which they may suffer from infertility problems. PCOS is characterized by a range of symptoms such as acne, menstrual irregularities, hirsutism, obesity, insulin resistance, anovulation and infertility. PCOS therapeutics include a wide a range of medications that are available in the worldwide. The global market for PCOS therapeutics can be segmented into six
By 2024, PCOS Drugs Market to Rise at 4.6% CAGR
The global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers and trends likely to impact the market during the forecast period. Growth of the global polycystic ovary syndrome drugs market is mainly driven by